)

Viking Therapeutics (VKTX) investor relations material
Viking Therapeutics Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Key clinical program updates
Lead compound VK2735, a dual GLP-1/GIP agonist, is in phase III for obesity with both subcutaneous and oral formulations advancing in trials.
Oral VK2735 showed up to 12% weight loss at 13 weeks in phase II, with durable effects and promising tolerability.
Subcutaneous VK2735 achieved nearly 15% weight loss at 13 weeks, with over 90% of efficacy retained at week 17.
Maintenance dosing regimens are being explored, with data supporting transition from high to lower doses while maintaining efficacy.
An amylin agonist is planned to enter clinical trials by late this year or early next year.
Safety, tolerability, and trial design insights
Most adverse events were mild to moderate, with GI events primarily occurring early and resolving quickly.
Slower titration rates are being used in phase III to improve tolerability, with real-world dosing expected to be individualized.
Placebo-controlled trials remain the regulatory standard, with patient retention aided by guaranteed access to active therapy post-trial.
BMI cutoffs for phase III trials align with industry standards, allowing inclusion of patients with comorbidities.
No regulatory path exists for maintenance-only approval; all studies focus on weight loss as the primary endpoint.
Strategic and market positioning
Over $800 million in cash provides runway to complete phase III trials and support aggressive development.
Lean operational model with just over 50 employees, leveraging external vendors for execution.
Direct-to-patient channels are seen as a major opportunity, reducing the need for large sales infrastructure.
Open to partnerships but prepared to commercialize in-house if needed, with a focus on building thoughtfully.
Success is defined by having multiple competitive products on the market and leveraging global direct-to-patient models.
Next Viking Therapeutics earnings date

Next Viking Therapeutics earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage